Gibson Dunn Advises Royalty Pharma on Acquisition of Royalty Interest in Amgen’s Imdelltra

In an acquisition of a royalty stake in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for a maximum of $950 million, Gibson Dunn is representing Royalty Pharma plc.